COVID-19 in Patients with Pre-Existing Interstitial Lung Disease : Potential Value of a Steroid-Based Treatment Strategy
The prognosis of patients with coronavirus disease 2019 (COVID-19) and pre-existing interstitial lung disease (preILD) is poor, and no effective treatment strategy has been determined. The aim of this study was to assess the effectiveness of a steroid-based treatment strategy for patients with COVID-19 and preILD. We retrospectively reviewed the medical records of 610 consecutive patients with COVID-19 treated at our institution between 1 March 2020 and 30 October 2021 and identified 7 patients with preILD, all of whom were treated with corticosteroids and remdesivir. All the patients were men with a median age of 63 years. Three of four patients with severe disease required invasive positive-pressure ventilation (n = 2) or nasal high-flow therapy (n = 1). All three patients could be weaned from respiratory support; however, one died in hospital. The remaining patient with severe COVID-19 had a do-not-resuscitate order in place and died while hospitalized. All three patients with moderate COVID-19 were discharged. The 30-day mortality was 0%, and the mortality rate during the entire observation period was 28.5%. The prognosis of our patients with COVID-19 and preILD has been better than in previous reports. Our management strategy using corticosteroids may have improved these patients' prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 12(2023), 15 vom: 27. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arai, Toru [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute exacerbation |
|---|
| Anmerkungen: |
Date Revised 14.08.2023 published: Electronic Citation Status Publisher |
|---|
| doi: |
10.3390/jcm12154940 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360678483 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360678483 | ||
| 003 | DE-627 | ||
| 005 | 20231226083525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12154940 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360678483 | ||
| 035 | |a (NLM)37568341 | ||
| 035 | |a (PII)4940 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arai, Toru |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 in Patients with Pre-Existing Interstitial Lung Disease |b Potential Value of a Steroid-Based Treatment Strategy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a The prognosis of patients with coronavirus disease 2019 (COVID-19) and pre-existing interstitial lung disease (preILD) is poor, and no effective treatment strategy has been determined. The aim of this study was to assess the effectiveness of a steroid-based treatment strategy for patients with COVID-19 and preILD. We retrospectively reviewed the medical records of 610 consecutive patients with COVID-19 treated at our institution between 1 March 2020 and 30 October 2021 and identified 7 patients with preILD, all of whom were treated with corticosteroids and remdesivir. All the patients were men with a median age of 63 years. Three of four patients with severe disease required invasive positive-pressure ventilation (n = 2) or nasal high-flow therapy (n = 1). All three patients could be weaned from respiratory support; however, one died in hospital. The remaining patient with severe COVID-19 had a do-not-resuscitate order in place and died while hospitalized. All three patients with moderate COVID-19 were discharged. The 30-day mortality was 0%, and the mortality rate during the entire observation period was 28.5%. The prognosis of our patients with COVID-19 and preILD has been better than in previous reports. Our management strategy using corticosteroids may have improved these patients' prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a acute exacerbation | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a interstitial lung disease | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a treatment strategy | |
| 700 | 1 | |a Kurahara, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Moda, Mitsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Takehiko |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuda, Yoshinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Kagawa, Tomoko |e verfasserin |4 aut | |
| 700 | 1 | |a Sugawara, Reiko |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuyuguchi, Kazunari |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Yoshikazu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 12(2023), 15 vom: 27. Juli |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:15 |g day:27 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm12154940 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 15 |b 27 |c 07 | ||